GLP-1 family
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2)
Davies M, Færch L, Jeppesen OK, et al. · Lancet · 2021
PMID: 33667417 · DOI: 10.1016/S0140-6736(21)00213-0
Summary
Phase 3 randomized, double-blind, double-dummy, placebo-controlled trial of subcutaneous semaglutide 2.4 mg vs 1.0 mg vs placebo over 68 weeks in adults with overweight/obesity and type 2 diabetes. Primary endpoint: change in body weight and HbA1c.
Citation hosted by NCBI. We link to the source so the researcher can read the abstract, full text, or references-cited list directly.
Compounds referenced in this study
- View product →GLP-1 SSingle-receptor incretin class agonist studied in incretin-pathway metabolic research.
Guides covering this compound
- How to read a peptide Certificate of AnalysisThe five numbers that actually matter on a peptide COA, what they mean, and the red flags that should make you choose a different supplier.7 min read
- HPLC vs mass spec vs amino acid analysis — what each test provesA practical guide to the three peptide QC methods, what each can prove and disprove, and why a complete QC profile requires all three.5 min read
- Made in the USA, and what that actually meansWhere our peptides are made, how we vet the active ingredient, and why independent per-lot testing matters more than any origin claim.3 min read
- How to evaluate a peptide supplier — a buyer's checklistTwelve questions every research customer should ask a peptide supplier before placing the first order, and what each answer reveals about the vendor's quality posture.4 min read
More GLP-1 family citations
- Once-Weekly Semaglutide in Adults with Overweight or ObesityN Engl J Med · 2021
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3)JAMA · 2021
- Tirzepatide Once Weekly for the Treatment of ObesityN Engl J Med · 2022